Combining a plasma-based microRNA signature with tumoral tissue expression of programmed cell death ligand 1 could help identify advanced non-small-cell lung cancer patients who are unlikely to benefit from immune checkpoint inhibition, suggests an exploratory study.
Clin Cancer Res 2019; doi:10.1158/1078-0432.CCR-18-1981
The presence of some autoimmune antibodies prior to treatment with programmed cell death protein 1 inhibitors is associated with both clinical benefit and immune-related adverse events in patients with non-small-cell lung cancer, researchers report.
The programmed cell death ligand 1 inhibitor avelumab has clinical activity and a manageable toxicity profile in patients with previously treated, unresectable malignant mesothelioma, according to phase Ib trial results.
Epidermal growth factor receptor-mutant non-small-cell lung cancer that transforms to small-cell lung cancer is characterized by a high rate of TP53 mutation and a lack of response to immunotherapy, among other features, show researchers.
Some patients with extensive-stage small-cell lung cancer may benefit from the addition of the poly(ADP ribose) polymerase inhibitor veliparib to standard chemotherapy, but further confirmation of its efficacy is needed, say researchers.
In light of recent reports of hyperprogression in response to treatment with cancer immunotherapy, medwireNews spoke to medical oncologist Razelle Kurzrock (University of California, San Diego, La Jolla, USA) about the phenomenon, the implications for therapy, and future directions for research.
Adjuvant erlotinib significantly prolongs disease-free survival, compared with a historic benchmark, in patients with epidermal growth factor receptor-mutated stage IA–IIIA non-small-cell lung cancer, US research shows.
Patients treated with immune checkpoint inhibitors are at increased risk for cardiovascular immune-related adverse events including those associated with myocarditis, pericardial disease, and vasculitis, suggests an analysis of the WHO pharmacovigilance database.
Patients with ALK-positive advanced non-small-cell lung cancer respond to the third-generation ALK and ROS1 tyrosine kinase inhibitor lorlatinib irrespective of previous ALK tyrosine kinase inhibitor treatment status, phase II study data show.
A modeling study presented at the 2018 NCRI Conference in Glasgow, UK, estimates that around 38% of the survival difference between older and younger patients with lung cancer may be due undertreatment in the older age group.
The CTONG-1103 EMERGING trial investigators believe that neoadjuvant treatment with epidermal growth factor receptor–tyrosine kinase inhibitors for stage IIIA-N2 non-small-cell lung cancer warrants further investigation.
The ALESIA trial comprising treatment-naïve patients with advanced anaplastic lymphoma kinase translocation-positive non-small-cell lung cancer confirms the systemic and intracranial efficacy of alectinib over crizotinib in an Asian population.
Vassiliki Papadimitrakopoulou outlines the candidate molecular mechanisms of acquired osimertinib resistance as revealed in the AURA3 trial and discusses the possibilities for later lines of treatment (4:12).
Analyses of the FLAURA and AURA3 trials presented at the ESMO 2018 Congress in Munich, Germany, shed light on the genetic mechanisms of acquired resistance to the third generation EGFR–tyrosine kinase inhibitor osimertinib.